MedTrace Logo

Chlamydia Trachomatis Immunology and Vaccinology Study

NCT01150747 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 347

Last updated 2015-12-03

No results posted yet for this study

Summary

The primary objective is to prospectively follow 200 women with or at risk of cervicitis to determine the chlamydia-specific cellular responses that correlate with protection against incident infection. The hypothesis is that a positive IFN-y response by peripheral CD4+ T cells responding to stimulation with HSP60 will be significantly associated with protection from incident C. trachomatis infection.

Conditions

  • Chlamydia

Interventions

DRUG

ceftriaxone

250mg IM once

DRUG

Azithromycin

1 gm once

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Harold Wiesenfeld

    lead OTHER

Principal Investigators

  • Toni Darville, MD · University of Pittsburgh

Eligibility

Min Age
15 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150747 on ClinicalTrials.gov